Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Cerus acquires mesothelin rights from Johns Hopkins University

Feb. 2, 2004

New phase I trial for RSR-13 in locally advanced NSCLC

Feb. 2, 2004

Bevacizumab inhibits tumor vascularity

Feb. 2, 2004

Exelixis scientists present new antiangiogenic ADAM-10 inhibitors

Feb. 2, 2004

Antitumor effects reported for erlotinib in metastatic head and neck cancer

Feb. 2, 2004

Xcytrin enters phase I trial in combination with Temodar for glioma

Jan. 30, 2004

Provectus prepares IND filing for Provecta

Jan. 30, 2004

Phase III Thymitaq trial cleared to continue by DSMB

Jan. 30, 2004

Merck and Jerini to develop small molecule inhibitors for cancer

Jan. 30, 2004

New antitumor agents developed by RIKEN scientists

Jan. 30, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.